



Journal Homepage: [-www.journalijar.com](http://www.journalijar.com)

## INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI:10.21474/IJAR01/21031

DOI URL: <http://dx.doi.org/10.21474/IJAR01/21031>



### RESEARCH ARTICLE

## COMPARATIVE EFFICACY OF THE METHANOL LEAF EXTRACT OF ARTEMISIA ANNUA AND AN ARTEMISININ COMBINATION THERAPY (ACT) IN THE TREATMENT OF PLASMODIUM BERGHEI INFECTION IN MICE

Echezona V. Agbo<sup>1</sup>, Ikenna O. Ezech<sup>1</sup>, Romanus C. Ezeokkonkwo<sup>1</sup> and Arinzechukwu S. Ezema<sup>2</sup>

1. Department of Veterinary Parasitology and Entomology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria.
2. Department of Veterinary Pathology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria.

### Manuscript Info

#### Manuscript History

Received: 27 March 2025

Final Accepted: 30 April 2025

Published: May 2025

#### Key words:-

Plasmodium Berghei, Artemisia Annu, ACT, Comparative Efficacy, Mice

### Abstract

This study investigated the comparative efficacy of different doses of the methanol leaf extract of *Artemisia annua* and a brand of ACT antimalarial drug, in *Plasmodium berghei*-infected mice. A total of thirty albino mice weighing between 20g and 40g were used for the study. They were randomly assigned into six groups (I-VI) of five mice each. All mice in groups I-V were infected with  $1 \times 10^5$  *Plasmodium berghei* suspended in 0.2 ml of phosphate-buffered saline. Group V was left untreated, whereas group VI served as the uninfected untreated control. Groups I, II, and III were treated respectively with 250 mg/kg, 500 mg/kg, and 1000 mg/kg of *Artemisia annua* methanol leaf extract for 4 days. Group IV was treated with 56 mg/kg ACT antimalarial drug, every day for 4 days. Parasitaemia, packed cell volume (PCV) and haemoglobin concentration (HB), were used to assess the efficacy of treatment. The Total leucocyte count (TLC) and Differential leucocyte count (DLC) were also determined. Parasitaemia became evident in all infected mice on day 7 PI. Parasitaemia was increased in groups I and II after treatment but was significantly decreased in groups III and IV. An overall significant decrease ( $P < 0.05$ ) in haemoglobin and PCV was seen, particularly in groups I, II, and V. However, a significant increase ( $P < 0.05$ ) in TLC was seen in all infected animals, with a sustained increase in groups I, II, and V after treatment. The infection caused a significant increase ( $P < 0.05$ ) in absolute lymphocyte, eosinophil, and monocyte counts of all infected groups, with a sustained increase in groups I, II, and V even after treatment. It is therefore concluded that the methanol leaf extract of *Artemisia annua* had significant efficacy as the ACT against *Plasmodium berghei* infection in mice at a dose of 1000 mg/kg body weight and justified its continual use as an herbal remedy against malaria in humans.

"© 2025 by the Author(s). Published by IJAR under CC BY 4.0. Unrestricted use allowed with credit to the author."

**Corresponding Author:-Echezona V. Agbo**

Address:-Department of Veterinary Parasitology and Entomology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria.

## Introduction:-

Malaria is one of the most common human infections worldwide and a leading cause of morbidity and mortality in endemic areas (10). Its impact has surpassed that of any other infectious disease globally, and it is endemic in over 90 countries, affecting a total population of 2.4 billion, which represents a significant portion of the world's population (9). According to the WHO, malaria is caused by the protozoan parasite of the *Plasmodium* genus. Between 300 and 500 million individuals are infected with *Plasmodium* spp., among these population, 1.5 to 2.7 million people, mostly children, die from the infection, Ninety percent of these deaths occur in Africa (9). In 2022, a WHO report stated that Nigeria accounted for 27% of global malaria cases and 31% of malaria deaths. Additionally, in December 2024, the BBC reported that Nigeria accounts for almost a third of those who die from malaria each year. The interactions among humans, mosquitoes, and the malaria parasite lead to malaria infection (20). The blood-feeding of infectious female *Anopheles* mosquitoes serves as the mode of malaria transmission (8). Five major *Plasmodium* species cause Malaria in humans, and they are *Plasmodium falciparum*, *Plasmodium malariae*, *Plasmodium ovale*, *Plasmodium vivax*, *Plasmodium knowlesi* (18). However, *Plasmodium falciparum* accounts for 60 – 70% of malaria deaths, being the most pathogenic among the *Plasmodium* species (27). Malaria is recognised as one of the diseases of economic importance to humans in Africa.

Severe malaria should be treated with highly effective drugs that have potency against the malaria parasite and are able to clear the infection within a short period without any complications (1). Antimalarial drug resistance has become a major threat to the treatment of malaria (18). Artemisinin combination therapy (ACT), in which the Artemisinin component is obtained from the plant *Artemisia annua* (*A. annua*), is currently the best therapy for the treatment of malaria (30). In Nigeria, there is still a high dependence on herbal medicine for the treatment of the disease, with a belief among some people that it is more effective than orthodox medicine (17). People in South-Eastern Nigeria use tea from boiled *Artemisia annua* leaves to treat malaria. A WHO report of 10<sup>th</sup> October 2019 does not support people using *Artemisia* plant material in any form for the treatment of malaria, citing that the herbal remedies are often insufficient to kill all malaria parasites in a patient's bloodstream, and their widespread use could hasten the development and spread of Artemisinin resistance. In this study, we compared a known Artemisinin combination therapy (ACT) Artemef<sup>®</sup> and the *Artemisia annua* leaf extract in the treatment of malaria in albino mice.

## Materials and Methods:-

### Experimental Animals

Thirty (30) adult albino mice weighing between 20g and 40g were used for the study. The mice were procured from the laboratory animal unit of the Faculty of Veterinary Medicine, University of Nigeria Nsukka. They were randomly assigned into six (6) groups of five (5) mice each. They were identified with body markings and housed throughout the study in clean plastic cages in the laboratory animal house of the Department of Veterinary Parasitology and Entomology, University of Nigeria Nsukka. The mice were acclimatized for 3 weeks before, and were provided clean water and proprietary mice feed ad libitum throughout the experiment.

### Plasmodium

The *Plasmodium* used in the study was obtained from the National Institute of Pharmaceutical Research and Development Abuja, Nigeria. They were then maintained by serial passage in mice which served as the donors for inoculation of the experimental mice.

### Plant Extract

The already dried and pulverized plant material of *Artemisia annua* was obtained from Nike, in Enugu State, Nigeria. It was then extracted in the Department of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Nigeria, using the cold maceration method (14) with 80% methanol. After extraction, the percentage yield was calculated

$$\% \text{ Yield} = \frac{\text{Weight of extract.}}{\text{Original weight of plant l}} \times 100$$

$$\frac{16.12\text{g} \times 100}{150\text{g}} = 1$$

and 10.75% was obtained.

Where weight of extract = 16.12g

Original weight of plant = 150g

### Experimental Design

The thirty mice were assigned into groups as follows:

Group 1: Infected and treated with *Artemisia annua* at 250mg/kg.

Group 2: Infected and treated with *Artemisia annua* at 500mg/kg.

Group 3: Infected and treated with *Artemisia annua* at 1000mg/kg.

Group 4: Infected and treated with ACT (Artemeter&Lumefantrine) at 56mg/kg.

Group 5: Infected and untreated.

Group 6: Uninfected and untreated.

### Infection of Experimental Animals

Each mouse in groups 1-5 was inoculated intraperitoneally with  $1.0 \times 10^5$  *Plasmodium berghei* suspended in 0.2ml of Phosphate buffered saline (PBS). The mice were screened from the 4<sup>th</sup> day postinfection (PI) by examining the stained thin blood smear to establish the onset and level of parasitemia.

The efficacy of the treatments were assessed using parasitaemia, packed cell volume (PCV), hemoglobin concentration (Hb), total erythrocyte count (TEC), total leucocyte count (TLC) and the differential leucocyte counts.

For the acute toxicity test, four groups of three mice each were administered methanol leaf extract of *Artemisia annua* at graded doses of 250 mg/kg, 500 mg/kg, 1000 mg/kg, and 2000 mg/kg body weight. Each group was housed separately, and the mice were closely monitored for clinical signs of toxicity, behavioral changes, and mortality for 24 hours post-administration.

Blood was collected from the tail vein by nipping a small portion of the tip of the tail with a pair of scissors. A thin smear was then made by milking the tail, placing a drop of blood on a clean grease-free microscope slide, and another slide was used to make a thin smear on the slide. The smear was then fixed with absolute methanol and stained with Giemsa stain. The slide was allowed to dry and then examined carefully under the microscope for *Plasmodium* parasitized red blood cells using  $\times 100$  objective lens (oil immersion). The level of parasitemia was then estimated by expressing the number of infected cells as a percentage of red blood cells (29).

Estimation of PCV was done using the microhaematocrit method (6). Blood was collected from the retro-orbital plexus of the median cantus of the eye into heparinized sample bottles. Heparinized haematocrit tubes were used to collect blood from the sample bottles by capillary action up to three-quarters full. One end was sealed with plasticine and centrifuged in a microhaematocrit centrifuge (Hawksley, England) at 10,000 revolutions per minute (rpm) for 5 minutes. The PCV was then read as a percentage using a microhaematocrit reader (Hawksley, England).

Hemoglobin concentration was determined using the cyanohaemoglobin method (21), 5mls of Drabkin's reagent was put in a clean test tube, and 20 $\mu$ l of blood was added to the reagent and mixed properly, the mixture was then allowed to react for 20 minutes, and the absorbance was read at 540nm wavelength against a reagent blank on a colorimeter (Lab-tech, India).

The red blood cells were counted using an improved Neuber chamber (6). Briefly, 4ml of RBC diluting fluid was added to test tubes in which 20 $\mu$ l of blood was equally added and mixed properly. The counting chamber was charged with the diluted cells, mounted on a microscope, and allowed to settle. The cells were then viewed using  $\times 40$  objective lens and counted in the four (4) edge squares and the inner square of the central square of the Neubauer chamber, and values were recorded with the aid of a tally counter. The number obtained was then multiplied by  $10^4$  and expressed as cells (millions) per cubic millimeter ( $\times 10^6$  cells/mm<sup>3</sup>).

The white blood cells were counted using the improved Neuber chamber (6). Here 380 $\mu$ l of WBC diluting fluid was added to the test tubes in which 20 $\mu$ l of blood was equally added and mixed properly. The counting chamber was charged with the diluted cells, mounted on a microscope, and allowed to settle. The cells were then viewed using  $\times 10$  objective lens and counted in the 4 corner squares and values were recorded with the aid of a tally counter. The number obtained was then multiplied by a factor of 50 and expressed as cells (thousand) per cubic millimeter ( $\times 10^3$  cells/mm<sup>3</sup>).


A thin blood smear was made on a grease-free microscope slide, allowed to dry and then stained with Giemsa staining technique (6). The smears were fixed in methanol for 2 minutes and then placed in a tank containing a 10% diluted Giemsa stain for 45 minutes. They were then rinsed with buffered distilled water (pH 6.8) and left to air dry. The different leucocyte proportions were enumerated and recorded. The values of the different proportions were then converted to absolute numbers based on the counts recorded for the total leucocyte count for each corresponding mouse.

Data collected were computed into means and standard error of means and analyzed using one way analysis of variance (ANOVA) using SPSS statistical software version 15.0 for windows. Means were separated using Duncan's multiple range test at Post hoc. Probability values of  $\geq 95$  were considered significant.

## Results:-


### clinical signs

The clinical signs observed in the mice include anaemia, emaciation, dullness, and anorexia. Wetting of the abdominal and anal region with urine was noticed in group administered with 2000mg/kg during the acute toxicity study.




**Fig1:-** Mean Parasitaemia of mice infected with *Plasmodium berghei* and treated with different doses of *Artemisia annua*

Fig 1 shows the mean parasitaemia. Parasitaemia became evident in all infected mice 7 days post infection. On day 10 post infection, there was an increase in parasitaemia in mice in groups 1, 2 and 5. On day 14 post infection, mice in groups 3 and 4 showed significantly lower ( $P < 0.05$ ) parasitaemia than groups 1, 2 and 5 with group 5 (infected control) having the highest parasitaemia




**Fig2:-**MeantotalErythrocytecountofmiceinfectedwithPlasmodiumbergheiandtreatedwithdifferent doses of Artemisia annua.

Fig 2 shows the mean total erythrocyte count. On day seven post infection, there was a significantly higher ( $p < 0.05$ ) total erythrocyte count in groups 3 and 4 than other groups, with group 5 (infected control) showing the lowest total erythrocyte count. On day 14 post infection, mice in groups 3, 4 and 6 had significantly higher ( $P < 0.05$ ) total erythrocyte count than those in groups 1, 2 and 5



**Fig3:-**MeanPCVofmiceinfectedwithPlasmodiumbergheiandtreatedwithdifferentdosesof Artemisia annua.


Fig 3 shows the mean PCV. At day 7 post infection, there was a higher PCV in mice in group 6 (uninfected treated) than mice in group 1 (250mg/kg). On day 14 post infection, mice in groups 3 and 4 had a significantly higher PCV ( $P<0.05$ ) than mice in groups 1 and 2



**Fig4:-**


MeanHaemoglobinconcentrationofmiceinfectedwithPlasmodiumbergheiiandtreatedwithdifferentdosesofArtemisiaannua.

Fig 4 shows the mean haemoglobin concentration. On the day of infection, mice in group 1 had the highest haemoglobin concentration than mice in other groups. On day 7 post infection, mice in group 1 showed the lowest haemoglobin concentration while group 6 (uninfected control) showed the highest. On day 14 post infection, there was a significantly higher ( $P<0.05$ ) haemoglobin concentration in groups 4 and 6 than those in group 1, 2, 3 and 5 with group 1 showing the lowest haemoglobin concentration.




**Fig5:-**MeanTotalLeucocytecountofmiceinfectedwithPlasmodiumbergheiiandtreatedwithdifferent doses of Artemisia annua.

Fig 5 shows the mean total leucocyte count (TLC). At day 7 post infection, mice in group 1 (250mg/kg) showed higher TLC than other groups, with group 2 (500mg/kg) showing the lowest TLC. On day 14 post infection, mice in groups 1, 2 and 5 had significantly higher ( $P<0.05$ ) TLC than those in groups 3, 4 and 6.




**Fig6:-**MeanLymphocyteofmiceinfectedwithPlasmodiumbergheiiandtreatedwithdifferentdosesofArtemisiaannua

Fig 6 shows the mean lymphocyte count. On day 7 post infection, there was no significant difference ( $P>0.05$ ) in the absolute lymphocyte count in mice in all the groups (group 1-6). On day 14 post infection, there was a significantly higher ( $P<0.05$ ) lymphocyte count in groups 1, 2 and 5 with the highest in group 1 than in groups 3, 4 and 6.




**Fig7:-**Mean Eosinophil of mice infected with *Plasmodium berghei* and treated with different doses of *Artemisia annua*.

Fig 7 shows the mean eosinophil count. On the day of infection, there was no significant difference ( $P > 0.05$ ) in the eosinophil count of mice in all the groups (groups 1-6). On day 7 post infection, mice in group 6 (uninfected control) had the lowest eosinophil count while mice in group 1 had the highest eosinophil count. On day 14 post infection, the eosinophil of mice in groups 3, 4 and 6 were significantly lower ( $P < 0.05$ ) than those in group 1, 2 and 5.



**Fig8:-**Mean Monocyte of mice infected with *Plasmodium berghei* and treated with different doses of *Artemisia annua*.

Fig 8 shows the mean monocyte count. On day 7 post infection, mice in group 3 had a significantly higher monocyte count than those in group 6 (uninfected control). On day 14 post infection, mice in group 1 (250mg/kg) had a significantly higher ( $p < 0.05$ ) monocyte count than all other groups of mice, while those in group 3 had the lowest count.





**Fig9:-**MeanNeutrophilofmiceinfectedwithPlasmodiumbergheiandtreatedwithdifferentdosesofArtemisiaannua.

Fig 9 shows the mean neutrophil count. On day 7 post infection, mice in groups 1 and 6 had significantly higher ( $p < 0.05$ ) neutrophil count than those in all other groups. On day 14 post infection, mice in group 5 had a significantly higher neutrophil count than mice in groups 1, 3, 4, 5 and 6.

### Survivability

The mice in groups 3, 4 and 6 all survived but those in groups 1, 2 and 5 all died.

### Discussion:-

Following the infection of the albino mice (Groups 1-5) with *Plasmodium berghei*, an average pre-patent period of 4 days was recorded. A similar pre-patent period has been recorded in mice elsewhere (23). The parasitaemia and anaemia observed in the infected groups were typical of *Plasmodium* infection (25)(31). Parasitaemia was cleared in group 3, following the administration of 1000mg/kg of the methanol leaf extract of *Artemisia annua*, and group 4 following the administration of 56 mg/kg of ACT. The parasitaemia in group 1(250mg/kg), 2(500mg/kg), and 5(infected control) continued to increase, which suggested a failure of the extract to inhibit the multiplication of the parasite in vivo at those doses.

The significant reduction in the mean total erythrocyte count and haemoglobin concentration in groups 1(250mg/kg), 2(500mg/kg), and 5(infected control) was thought to be as a result of continued increase in parasitaemia and destruction of red blood cells as also reported by (31).

Leucocytosis was observed in all infected groups, as previously reported by (24)(5). Leucocytosis persisted in the groups treated with 250mg/kg, 500mg/kg, and the infected control as the study progressed, but the group treated with 1000mg/kg and 56 mg/kg ACT showed a return of leucocytes to the pre-infection values. This suggested that the extract did stop the leucocytosis caused by the multiplication of the parasite at the low and medium doses, but had an effect on the parasite when the medium dose was doubled at 1000mg/kg, an effect similar to and comparable with that of the ACT. Leucocytosis in malaria infection is the result of the immune response to the parasite invasion of the red blood cells, causing an increased proliferation of leucocytes in response to the infection (5). Leucocytosis had been reported to be associated with the severity of, and mortality seen in malaria patients (13).

There was no significant change in the mean lymphocyte count on day 7 post-infection, but lymphocytosis was noticed as the infection progressed. There was a significant increase in lymphocyte count in groups 1(250mg/kg), 2(500mg/kg) and the infected control, which has also been recorded by (26)(22).

Eosinophilia was noticed in all infected groups, which returned to the normal baseline level pre-infection in group 3 (1000mg/kg) and group 4 (ACT). Eosinopenia has been reported in malaria infection (19)(11), but cases of Eosinophilia have also been reported in malaria (12)(16). The activation of the eosinophils is believed to be a result of the inflammatory and immune response to the parasite (12).

Monocytosis seen in malaria has been reported by (3) (10) to be due to activation of the innate immune response to the malaria parasite, phagocytosis of infected cells/parasite, Cytokine secretion, and antigen presentation. This report agrees with the findings from the study, which showed monocytosis in the infected group, but was only reversed in the groups treated with 1000mg/kg and ACT, suggesting the clearance of the *Plasmodium* parasite from the bloodstream, leading to the return of the mean absolute monocyte count to near pre-infection values.

Neutrophil function in malaria is understudied (4)(2). Some researchers have reported Neutropenia to be found in acute and severe malaria (7)(28), while some have reported cases of Neutrophilia (15). From the study, there was mild neutropenia in all infected groups except group 1(250mg/kg), which was gradually returning to normal count in all infected groups. There was no significant difference in the neutrophil count in group 1, while neutrophilia was observed in group 6 (uninfected control), which returned to normal on day 14. These differences in the mean neutrophil count call for further studies into neutrophils in malaria infection.

### Conclusion:-

From the study, it was concluded that the methanol leaf extract of *Artemisia annua* was efficacious against *Plasmodium berghei* infection in mice at 1000 mg/kg. at this dose, the extract had a comparable efficacy to Artemef®. The efficacy of *Artemisia annua* was dose-dependent, showing the highest observed activity at 1000mg/kg body weight.

### Declaration of Conflicting Interest

The authors declare no potential conflict of interest with respect to the research, authorship, and publication of this article.

### References:-

1. Achan, J., Barry, A., Leroy, D., Kamara, G., Duparc, S., WiwekaKaszubska, Gandhi, P., Bénédicte Buffet, Tshilab, P., Bernhards Ogutu, Taylor, T., Krishna, S., Richardson, N., Hanu Ramachandrani and Rietveld, H. (2024). Defining the next generation of severe malaria treatment: a target product profile. *Malaria journal*, 23(1). doi:https://doi.org/10.1186/s12936-024-04986-z.
2. Aitken, E.H., Alemu, A. and Rogerson, S.J. (2018). Neutrophils and Malaria. *Frontiers in Immunology*, 9. doi:https://doi.org/10.3389/fimmu.2018.03005.
3. Antwi-Baffour, S., Kyeremeh, R., Buabeng, D., Adjei, J.K., Aryeh, C., Kpentey, G. and Seidu, M.A. (2018). Correlation of malaria parasitaemia with peripheral blood monocyte to lymphocyte ratio as indicator of susceptibility to severe malaria in Ghanaian children. *Malaria Journal*, 17(1). doi:https://doi.org/10.1186/s12936-018-2569-x.
4. Babatunde, K.A. and Adenuga, O.F. (2022). Neutrophils in malaria: A double-edged sword role. *Frontiers in Immunology*, 13. doi:https://doi.org/10.3389/fimmu.2022.922377.
5. Bertrand Njewa, Eyong, J. and Ebai, C.B. (2024). Malaria parasitaemia and its impact on biological parameters among children <16 years old attending the Nkwen District Hospital, Cameroon. *PubMed*, 15, pp.3–3. doi:https://doi.org/10.5281/zenodo.10731943.
6. Coles, E.H. (1986). *Veterinary clinical pathology*. Philadelphia, Pa.: Saunders.
7. Dale, D.C. and Wolff, S.M. (1973). Studies of the Neutropenia of Acute Malaria. *Blood*, 41(2), pp.197–206. doi:https://doi.org/10.1182/blood.v41.2.197.197.
8. Fikadu, M. and Ashenafi, E. (2023). Malaria: An Overview. *Malaria: An overview*, Volume 16(16), pp.3339–3347. doi:https://doi.org/10.2147/idr.s405668.
9. Garcia, L.S. (2010). Malaria. *Clinics in Laboratory Medicine*, [online] 30(1), pp.93–129. doi:https://doi.org/10.1016/j.cll.2009.10.001.
10. Keh Min Xuan, Nurhidanatasha Abu Bakar, Mohd, K. and Azlan, M. (2023). The role of monocytes in malaria infection. doi:https://doi.org/10.5114/ceji.2023.126650.
11. Kini, R.G. and Jayaprakash Chandrashekhar (2016). Parasite and the Circulating Pool- Characterisation of Leukocyte Number and Morphology in Malaria. *Journal of Clinical and Diagnostic Research*. doi:https://doi.org/10.7860/jcdr/2016/16425.7887.
12. Kurtzhals, Reimert, Tette, Dunyo, Koram, Akanmori, Nkrumah and Hviid (1998). Increased eosinophil activity in acute *Plasmodium falciparum* infection-association with cerebral malaria. *Clinical and Experimental Immunology*, [online] 112(2), pp.303–307. doi:https://doi.org/10.1046/j.1365-2249.1998.00586.x.
13. Ladhani, S., Lowe, B., Cole, A.O., Kowuondo, K. and Newton, C.R.J.C. (2002). Changes in white blood cells and platelets in children with *falciparum* malaria: relationship to disease outcome. *British Journal of Haematology*, 119(3), pp.839–847. doi:https://doi.org/10.1046/j.1365-2141.2002.03904.x.
14. Madubunyi, I.I., Onoja, S.O. and Asuzu, I.U. (2010). In vitro antioxidant and in vivo antidiabetic potential of the methanol extract of *Ficus glumosa* Del (Moraceae) stem bark in alloxan-induced diabetic mice. *Comparative Clinical Pathology*, 21(4), pp.389–394. doi:https://doi.org/10.1007/s00580-010-1103-5.
15. Maina, R.N., Walsh, D., Gaddy, C., Hongo, G., Waitumbi, J., Otieno, L., Jones, D. and Ogutu, B.R. (2010). Impact of *Plasmodium falciparum* infection on haematological parameters in children living in Western Kenya. *Malaria Journal*, 9(S3). doi:https://doi.org/10.1186/1475-2875-9-s3-s4.
16. Orish, V.N., Ofori-Amoah, J., Amegan-Aho, K.H., Osisiogu, E.U., Osei-Yeboah, J., Lokpo, S.Y., Allotey, E.A., Adu-Amankwaah, J.A., Azuma, D.E. and Agordoh, P.D. (2021). Eosinophilia in school-going children with *plasmodium falciparum* and helminth infections in the Volta region of Ghana. *Pan African Medical Journal*, 38. doi:https://doi.org/10.11604/pamj.2021.38.277.17379.
17. Osuchukwu, N., Eko, J., Abia, R. and Ochei, K. (2017). Use of Herbal Medicine among Adult Residents in Calabar Metropolis, Cross River State, Nigeria. *Journal of Complementary and Alternative Medical Research*, 2(3), pp.1–14. doi:https://doi.org/10.9734/jocamr/2017/31725.
18. Parija, S.C. and Antony, H.A. (2016). Antimalarial drug resistance: An overview. *Tropical Parasitology*, [online] 6(1), p.30. doi:https://doi.org/10.4103/2229-5070.175081.
19. Sakzabre, D., Asiamah, E.A., Akorsu, E.E., Abaka-Yawson, A., Dika, N.D., Kwasi, D.A., Ativi, E., Tseyiboe, C. and Osei, G.Y. (2020). Haematological Profile of Adults with Malaria Parasitaemia Visiting the Volta Regional Hospital, Ghana. *Advances in Hematology*, 2020, pp.1–6. doi:https://doi.org/10.1155/2020/9369758.

20. Savi, M.K. (2022). An Overview of Malaria Transmission Mechanisms, Control, and Modeling. *Medical Sciences*, 11(1), p.3. doi:<https://doi.org/10.3390/medsci11010003>.
21. Schalm, O.W., Jain, N.C. and Carroll, E.J. (1975). *Veterinary Hematology*.
22. Sokhna Keita Alassane, Marie-Laure Nicolau-Travers, Menard, S., Olivier Andreoletti, Jean-Pierre Cambus, Noémie Gaudre, Wlodarczyk, M., Blanchard, N., Berry, A., Abbes, S., Colongo, D., Faye, B., Jean-Michel Augereau, Lacroux, C., Iriart, X. and Françoise Benoit-Vical (2017). Young Sprague Dawley rats infected by *Plasmodium berghei*: A relevant experimental model to study cerebral malaria. *PLoS ONE*, 12(7), pp.e0181300–e0181300. doi:<https://doi.org/10.1371/journal.pone.0181300>.
23. Stanway, R.R., Bushell, E., Chiappino-Pepe, A., Roques, M., Sanderson, T., Franke-Fayard, B., Caldelari, R., Golomingi, M., Nyonda, M., Pandey, V., Schwach, F., Chevalley, S., Ramesar, J., Metcalf, T., Herd, C., Burda, P.-C., Rayner, J.C., Soldati-Favre, D., Janse, C.J. and Hatzimanikatis, V. (2019). Genome-Scale Identification of Essential Metabolic Processes for Targeting the *Plasmodium* Liver Stage. *Cell*, [online] 179(5), pp.1112-1128.e26. doi:<https://doi.org/10.1016/j.cell.2019.10.030>.
24. Tiiba, J.-D.I., Ahmadu, P.U., Naamawu, A., Fuseini, M., Raymond, A., Osei-Amoah, E., Bobrtaa, P.C., Bachehie, P.P., Abdulai, M.A., Alidu, I., Alhassan, A., Abdul Hamid, J.G., Yussif, A., Tayawn, P.T., Sakyi, A.A., Yeng, T.N., Aziz, S.A., Mankana, A.-H., Husein, W.A. and Abdallah, A.-K.W. (2022). Thrombocytopenia a predictor of malaria: how far? *Journal of Parasitic Diseases*. doi:<https://doi.org/10.1007/s12639-022-01557-4>.
25. Tine, R.C., Ndiaye, M., Hansson, H.H., Ndour, C.T., Faye, B., Alifrangis, M., Sylla, K., Ndiaye, J.L., Magnussen, P., Bygbjerg, I.C. and Gaye, O. (2012). The association between malaria parasitaemia, erythrocyte polymorphisms, malnutrition and anaemia in children less than 10 years in Senegal: a case control study. *BMC Research Notes*, 5(1). doi:<https://doi.org/10.1186/1756-0500-5-565>.
26. Tobón-Castaño, A., Mesa-Echeverry, E. and Miranda-Arboleda, A.F. (2015). Leukogram Profile and Clinical Status in vivax and falciparum Malaria Patients from Colombia. *Journal of Tropical Medicine*, [online] 2015, p.e796182. doi:<https://doi.org/10.1155/2015/796182>.
27. Trivedi, V., Balaji, S. and Deshmukh, R. (2020). Severe malaria: Biology, clinical manifestation, pathogenesis and consequences. *Journal of Vector Borne Diseases*, 57(1), p.1. doi:<https://doi.org/10.4103/0972-9062.308793>.
28. van Wolfswinkel, M.E., Vliegenthart-Jongbloed, K., de Mendonça Melo, M., Wever, P.C., McCall, M.B., Koelewijn, R., van Hellemond, J.J. and van Genderen, P.J. (2013). Predictive value of lymphocytopenia and the neutrophil-lymphocyte count ratio for severe imported malaria. *Malaria Journal*, 12(1), p.101. doi:<https://doi.org/10.1186/1475-2875-12-101>.
29. Warhurst, D.C. and Williams, J.E. (1996). ACP Broadsheet no 148. July 1996. Laboratory diagnosis of malaria. *Journal of Clinical Pathology*, [online] 49(7), pp.533–538. doi:<https://doi.org/10.1136/jcp.49.7.533>.
30. Weathers, P.J. (2014). Dried-leaf *Artemisia annua*: A practical malaria therapeutic for developing countries? *World Journal of Pharmacology*, 3(4), p.39. doi:<https://doi.org/10.5497/wjp.v3.i4.39>.
31. White, N.J. (2018). Anaemia and malaria. *Malaria Journal*, [online] 17(1). doi:<https://doi.org/10.1186/s12936-018-2509-9>.